KALAKALA BIO, Inc.

Nasdaq kalarx.com


$ 6.32 $ 0.12 (1.94 %)    

Thursday, 25-Apr-2024 10:07:40 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 6.3
$ 6.32
$ 0.00 x 0
$ 6.47 x 100
$ 6.32 - $ 6.32
$ 5.10 - $ 19.35
5,721
na
15.32M
$ 0.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-03-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 02-12-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 04-02-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-31-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-kala-bio-lowers-price-target-to-21

HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $22 to ...

 oppenheimer-reiterates-outperform-on-kala-bio-maintains-15-price-target

Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.

 hc-wainwright--co-maintains-buy-on-kala-bio-lowers-price-target-to-22

HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to ...

 kala-bio-q3-earnings-insights
Kala Bio: Q3 Earnings Insights
11/13/2023 13:30:13

 kala-pharmaceuticals-q3-eps-341-misses-215-estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-reiterates-buy-on-kala-bio-maintains-24-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:KALA) with a Buy and maintains $24 price target.

 kala-pharmaceuticals-q2-eps-436-up-from-1892-yoy-592m-in-cash-cash-equivalents-and-short-term-expected-to-fund-operations-into-2q-2025

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.36) per share. This is a 76.96 percent increase over losses...

 kala-pharmaceuticals-announces-name-change-to-kala-bio-effective-august-2-2023

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and...

 10-short-squeeze-stocks-to-watch-aeglea-biotherapeutics-toro-corp-airsculpt-a-company-moves-up-4166-positions--more

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for th...

 10-short-squeeze-stocks-to-watch-toro-corp-paxmedica-getty-images-and-more

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the n...

 hc-wainwright--co-reiterates-buy-on-kala-pharmaceuticals-raises-price-target-to-24

HC Wainwright & Co. analyst Yi Chen reiterates Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and raises the price target...

 kala-pharmaceuticals-q1-earnings-insights

Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what invest...

 kala-pharmaceuticals-q1-eps-699-misses-568-estimate-cash--cash-equivalents-of-636m-with-anticipated-funding-under-the-cirm-award-will-enable-it-to-fund-operations-into-q1-of-2025

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(6.99) per share which missed the analyst consensus estimate o...

 5-short-squeeze-stocks-to-watch-getty-images-bullfrog-ai-and-a-new-leader-for-the-week

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the n...

 10-short-squeeze-stocks-to-watch-getty-images-bullfrog-ai-and-a-stock-moving-up-1687-positions-on-leaderboard

Potential shorts squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the ...

 hc-wainwright--co-reiterates-buy-on-kala-pharmaceuticals-maintains-22-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Kala Pharmaceuticals (NASDAQ:KALA) with a Buy and maintains $22 price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION